We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

688072:SSEPiotech, Inc. Class A Analysis

Data as of 2026-05-29 - not real-time

CN¥637.98

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Piotech Inc. is trading at roughly double its discounted cash‑flow fair value of ≈288 CNY, with a trailing PE of 109 versus an industry average of 41, indicating significant overvaluation. The company nonetheless showcases robust fundamentals: revenue surged 57% YoY, gross margin sits at 35%, operating margin 15%, and ROE exceeds 25%, while cash on hand more than doubles total debt, underscoring a strong balance sheet and a sustainable dividend (payout ratio under 5%).
Technically, the stock is in a bullish regime—price is above the 20‑, 50‑ and 200‑day SMAs, RSI is at 62, and MACD shows a bullish crossover, with volume trending upward. However, volatility is extremely high at nearly 89% over the past 30 days, and the beta is effectively neutral, suggesting price swings are driven more by company‑specific factors than market movements. These dynamics imply short‑term upside potential may be limited by a likely correction, while the longer‑term growth narrative remains compelling.

Market Outlook

Short Term

< 1 year
Cautious
Model confidence: 7/10

Key Factors

  • Current price far exceeds DCF fair value
  • High short‑term volatility and near‑overbought RSI
  • Technical bullishness may be short‑lived without valuation support

Medium Term

1–3 years
Neutral
Model confidence: 6/10

Key Factors

  • Sustained revenue growth and strong cash generation
  • Valuation still compressed relative to fundamentals
  • Exposure to Chinese semiconductor policy and export controls

Long Term

> 3 years
Positive
Model confidence: 7/10

Key Factors

  • Secular demand for advanced semiconductor equipment in China
  • High ROE, solid margins, and low leverage
  • Potential for valuation re‑rating as the company captures market share

Key Metrics & Analysis

Financial Health

Revenue Growth57.00%
Profit Margin23.75%
P/E Ratio109.1
ROE25.11%
ROA3.54%
Debt/Equity34.67
P/B Ratio24.8
Op. Cash FlowCN¥3.1B
Free Cash FlowCN¥2.2B
Industry P/E40.9

Technical Analysis

TrendBullish
RSI62.0
SupportCN¥402.32
ResistanceCN¥779.00
MA 20CN¥560.57
MA 50CN¥450.67
MA 200CN¥327.80
MACDBullish
VolumeIncreasing
Fear & Greed Index93.32

Valuation

Fair ValueCN¥288.65
GradeOvervalued
TypeGrowth
Dividend Yield0.04%

Risk Assessment

Beta0.06
Volatility88.69%
Sector RiskMedium
Reg. RiskHigh
Geo RiskHigh
Currency RiskMedium
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.